US Patent

US12433859 — Oral solutions comprising lisdexamfetamine salts

Method of Use · Assigned to Adalvo Ltd · Expires 2040-04-16 · 14y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a stable oral pharmaceutical solution formulation of lisdexamfetamine salts with a pH between 5.5 and 9.0.

USPTO Abstract

Oral pharmaceutical solution comprising a pharmaceutically acceptable salt of lisdexamfetamine, and a pharmaceutically acceptable aqueous carrier comprising a buffer and a cosolvent selected from the group consisting of a glycol, a polyol, and a mixture thereof, wherein the pH of the solution is from 5.5 to 9.0. The oral pharmaceutical solution presents excellent physicochemical stability, even under alkaline conditions.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-842 — lisdexamfetamine-dimesylate

Patent Metadata

Patent number
US12433859
Jurisdiction
US
Classification
Method of Use
Expires
2040-04-16
Drug substance claim
No
Drug product claim
Yes
Assignee
Adalvo Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.